Drug Profile
SDC 1802
Alternative Names: SDC-1802Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator Sareum
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
Most Recent Events
- 30 Apr 2022 Sareum Holdings has patent protection for SDC 1802 molecule and pharmaceutical preparations thereof in European Union
- 03 Dec 2020 Preclinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma in United Kingdom (PO) (Sareum website, December 2020)
- 28 Aug 2020 No recent reports of development identified for research development in Precursor-T-cell-lymphoblastic-leukaemia-lymphoma in United Kingdom (PO)